Pembrolizumab may leads to higher quality of life (Change from baseline to week 15) compared with chemotherapy (low certainty).
Pembrolizumab probably leads to higher response rate (partial and complete response) compared with chemotherapy (moderate certainty).
Pembrolizumab showed no clear difference in treatment‐related mortality compared with chemotherapy (low certainty).
Pembrolizumab showed no clear difference in discontinuation due to adverse event compared with chemotherapy (low certainty).
Pembrolizumab may leads to lower serious adverse events (irrespective of attribution to treatment) compared with chemotherapy (low certainty).
Combination probably leads to lower overall survival compared with single‐agent chemotherapy (moderate certainty).
Combination leads to higher tumour response compared with single‐agent chemotherapy (high certainty).
Combination probably leads to lower time to progression compared with single‐agent chemotherapy (moderate certainty).
Combination showed no clear difference in treatment‐related death compared with single‐agent chemotherapy (moderate certainty).
Escalated BEACOPP leads to lower mortality compared with chemotherapy including ABVD (high certainty).
Escalated BEACOPP probably leads to lower progression, relapse or death compared with chemotherapy including ABVD (moderate certainty).
Escalated BEACOPP showed no clear difference in adverse event: treatment‐related mortality compared with chemotherapy including ABVD (low certainty).
Escalated BEACOPP showed no clear difference in adverse event: secondary malignancies compared with chemotherapy including ABVD (low certainty).
Escalated BEACOPP may leads to higher adverse event: secondary malignancies: AML or MDS compared with chemotherapy including ABVD (low certainty).
It is very uncertain whether escalated BEACOPP changes adverse event: infertility (secondary amenorrhoea) compared with chemotherapy including ABVD (very low certainty).
The review found no eligible studies for this question.
Fewer showed no clear difference in secondary malignant neoplasms compared with more courses of chemotherapy (with or without radiotherapy (moderate certainty).
Fewer showed no clear difference in death compared with more courses of chemotherapy (with or without radiotherapy (high certainty).
Fewer showed no clear difference in progression/relapse compared with more courses of chemotherapy (with or without radiotherapy (high certainty).